Community management: An effective model to reduce medication discontinuation rate in patients with schizophrenia.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 41511922.
- Also identified by DOI 10.1371/journal.pone.0324114 and PMC identifier 12788679.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Medication discontinuation is highly prevalent among patients with schizophrenia and is associated with poor clinical outcomes. Although community-based management models have been implemented in China to support patients, recent evidence of their effectiveness in reducing medication discontinuation rates remains limited. In this cross-sectional study, we surveyed 1,531 patients with schizophrenia under community management in Chengdu, China, using a multi-stage sampling approach. Data on treatment discontinuation (defined as cessation of all antipsychotics for >15 days without medical advice), socio-demographics, clinical characteristics, and service utilization were collected via face-to-face interviews. Univariate and multivariable logistic regression analyses were used to identify the factors associated with medication discontinuation. The overall rate of medication discontinuation was 4.1%. Multivariable analysis identified several independent risk factors for discontinuation: weak stable disease state (adjusted odds ratio [aOR] = 2.70, 95% confidence interval [CI]: 1.34-5.24), lack of insight (aOR for partial vs. no insight = 0.25, 95% CI: 0.08-0.80; aOR for full vs. no insight = 0.18, 95% CI: 0.05-0.65), presence of noticeable side effects (aOR = 1.98, 95% CI: 1.05-3.64), and absence of regular follow-up (aOR for intermittent vs. no follow-up = 0.38, 95% CI: 0.20-0.72; aOR for regular vs. no follow-up = 0.22, 95% CI: 0.10-0.44). Community management was associated with a low rate of medication discontinuation in patients with schizophrenia. Key modifiable factors, including disease stability, insight, medication side effects, and follow-up adherence should be prioritized in community-based interventions to further improve treatment continuity.
Medical subject headings
- Schizophrenia
- Antipsychotic Agents